Pharvaris N.V.

PHVS | NASDAQ

Price Alert Chart Builder DCF Calculator

$35.44

-$0.58 (-1.61%)

Sep 22, 2026, 11:40 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Pro Subscription

Upgrade now for unlimited access to all data, tools and no ads.

Upgrade now ➞

Related Stocks

Company	Yield
ARDX Ardelyx	N/A
BCRX BioCryst Pharmaceuticals	N/A
IMNM Immunome	N/A
MAZE Maze Therapeutics	N/A
NTLA Intellia Therapeutics	N/A
ORIC ORIC Pharmaceuticals	N/A
SYRE Spyre Therapeutics	N/A
UPB Upstream Bio	N/A
VERA Vera Therapeutics	N/A
ZYME Zymeworks	N/A

Dividend Rankings ➞

Recent News

6 days ago / defenseworld.net
Anne Lesage Sells 30,000 Shares of Pharvaris (NASDAQ:PHVS) Stock
6 days ago / defenseworld.net
Pharvaris N.V. $PHVS Position Trimmed by Squarepoint Ops LLC
6 days ago / seekingalpha.com
Pharvaris N.V. (PHVS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
7 days ago / zacks.com
PHVS Stock Rises 10% in a Month: What Is Driving the Rally?
13 days ago / seekingalpha.com
Pharvaris: 'Strong Buy' Based On Deucrictibant PDUFA And Prophylaxis Trial Win
14 days ago / seekingalpha.com
Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary Angioedema Transcript
14 days ago / reuters.com
Pharvaris' genetic disorder drug meets main goal in late-stage trial
1 month ago / globenewswire.com
Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update
2 months ago / globenewswire.com
Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology
2 months ago / zacks.com
Wall Street Analysts Think Pharvaris (PHVS) Could Surge 43.03%: Read This Before Placing a Bet